Genentech R&D Spending Will Be 18% Of Revenue; Small Molecules In Plan
Genentech's long-term research & development investment will more closely resemble that of a pharmaceutical firm than a biotech company
You may also be interested in...
Genentech believes the first competitor to its oncologic Avastin in the angiogenesis market is "years away.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011